Cargando…
Basic fundamentals of drug delivery /
Basic Fundamentals of Drug Delivery covers the fundamental principles, advanced methodologies and technologies employed by pharmaceutical scientists, researchers and pharmaceutical industries to transform a drug candidate or new chemical entity into a final administrable drug delivery system. The bo...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
London, United Kingdom ; San Diego, CA :
Academic Press, an imprint of Elsevier,
[2019]
|
| Colección: | Advances in pharmaceutical product development and research series.
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Front Cover; Basic Fundamentals of Drug Delivery; Copyright Page; Dedication; Contents; List of Contributors; About the Editor; 1 Scientific Rationale for Designing Controlled Drug Delivery Systems; 1.1 Conventional Drug Delivery Systems and Limitations; 1.2 Controlled Release Drug Delivery System; 1.2.1 Historical Perspective; 1.2.2 Concept and Understanding; 1.2.3 Advantages of CRDDS Over Conventional Delivery Systems; 1.2.4 Compounds That Are Unsuitable for CRDDS; 1.3 Design of CRDDS: Understanding of Factors; 1.3.1 Physicochemical Properties of Drug and Design Considerations
- 1.3.2 Pharmacokinetic/Dynamic Considerations1.3.3 Polymers for CRDDS; 1.3.3.1 Synthetic Polymers; 1.3.3.2 Natural Polymers; 1.3.3.3 Smart Polymers; 1.3.3.3.1 pH-sensitive Polymers; 1.3.3.3.2 Temperature Sensitive Polymers; 1.3.3.3.3 Ion Exchange Polymers; 1.4 Approaches for the Design of CRDDS; 1.4.1 Chemical Approach; 1.4.2 Biological Approach; 1.4.3 Pharmaceutical Approach; 1.5 Medical Rationale of CRDDS; 1.5.1 Reduction in Dosing Frequency; 1.5.2 Lesser Drug Exposure to the Biological Environment; 1.5.3 Minimization of Plasma Concentration Fluctuations; 1.5.4 Better Patient Compliance
- 1.5.5 Lower Adverse/Side Effects1.5.6 Augmented Efficacy; 1.6 The Biological Rationale for CRDDS; 1.6.1 Absorption; 1.6.2 Drug-Protein Binding; 1.6.3 Distribution; 1.6.4 Elimination; 1.6.5 Dose-Dependent Bioavailability; 1.6.6 Duration of Drug Residence Within the Therapeutic Window; 1.6.7 Better Safety Margin; 1.6.8 Individualization in a Diseased Condition; 1.7 Conclusion; Acknowledgment; Abbreviations; References; 2 Current Developments in Excipient Science: Implication of Quantitative Selection of Each Excipient in Product Development; 2.1 An Introduction to Excipient Science
- 2.1.1 History of Use of Excipients in Pharmaceutical Formulations2.1.2 Need and Rationale Behind the Use of Excipients; 2.1.3 Why Is the Pharma Industry Not Taking Interest to Develop and Use Novel Excipients?; 2.1.4 Role of Excipients in Pharmaceutical Formulations; 2.1.5 Criteria for Selection of Excipients; 2.1.6 Coprocessed Excipients; 2.1.7 Ideal Properties of Excipients; 2.2 Excipients Used in Different Dosage Formulations: Role in Product Development; 2.2.1 Excipients Used in the Solid Dosage Form; 2.2.1.1 Antiadherent and Lubricants; 2.2.1.2 Binders; 2.2.1.3 Disintegrants
- 2.2.1.3.1 Characteristics of Disintegrants2.2.1.3.2 Factors Affecting the Action of Disintegrants; 2.2.1.4 Fillers; 2.2.1.4.1 Sugars; 2.2.1.4.2 Lactose; 2.2.1.4.3 Dextrose; 2.2.1.4.4 Sucrose; 2.2.1.4.5 Mannitol; 2.2.1.4.6 Starch and Its Derivatives; 2.2.1.4.7 Celluloses; 2.2.1.4.8 Inorganic Compounds; 2.2.1.5 Flavoring Agents; 2.2.1.6 Sweeteners; 2.2.1.7 Coloring Agent; 2.2.1.8 Glidants; 2.2.1.9 Sorbents; 2.2.1.10 Preservatives; 2.2.2 Excipients Used in the Liquid Dosage Form; 2.2.2.1 Solvents; 2.2.2.2 Cosolvents; 2.2.2.3 Sequestering Agents; 2.2.2.4 Buffers and Buffering Agents; 2.2.2.5 Flavoring Agents